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with Crohn’s; TNF, tumor necroUp to 30% of patients with Crohn’s disease (CD) require surgery within the first 5 years from
diagnosis. We investigated the recent risk of bowel surgery in an inception cohort of pediatric
patients with CD and whether early use of biologics (tumor necrosis factor antagonists) alters
later disease course.METHODS: We collected data from the Pediatric Inflammatory Bowel Disease Collaborative Research
Group registry on 1442 children (age, £16 y) diagnosed with CD from January 2002
through December 2014. Data were collected at diagnosis, 30 days following diagnosis, and
then quarterly and during hospitalizations for up to 12 years. Our primary aim was to
determine the 10-year risk for surgery in children with CD. Our secondary aim was
to determine whether early use of biologics (<3 mo of diagnosis) affected risk of disease
progression.RESULTS: The 10-year risk of first bowel surgery was 26%. The 5-year risk of bowel surgery did not
change from 2002 through 2014, and remained between 13% and 14%. Most surgeries
occurred within 3 years from diagnosis. The only predictor of surgery was disease behavior at
diagnosis. CD with inflammatory behavior had the lowest risk of surgery compared to stric-
turing disease, penetrating disease, or both. We associated slowing of disease progression to
stricturing or penetrating disease (but not surgery) with early use of biologics, but this effect
only became evident after 5 years of disease. Our results indicate that biologics slow disease
progression over time (hazard ratio, 0.85; 95% CI, 0.76–0.95).CONCLUSIONS: In an analysis of data from a registry of pediatric patients with CD, we found that
among those with significant and progressing disease at or shortly after presentation,r: CD, Crohn’s disease; IBD, inflammatory
atification and Identification of Immuno-
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sis factor.
early surgery is difficult to prevent, even with early use of biologics. Early use of biologics
(<3 mo of diagnosis) can delay later disease progression to stricturing and/or penetrating
disease, but this affect could become evident only years after initial management decisions
are made.Keywords: IBD; Treatment; Anti-TNF Therapy; Risk Factor; PIBDCRG.Crohn’s disease (CD) is a chronic, frequentlyprogressive inflammatory disorder characterized
by an exaggerated mucosal immune response of the
gastrointestinal system in a genetically susceptible indi-
vidual.1 CD and ulcerative colitis are the 2 major clinical
phenotypes and affect approximately 1 in 200 people in
the Western world, with an increasing prevalence in
developing countries.2–4 More than 50% of children are
expected to develop complicated disease behavior
(stricturing and/or penetrating behavior) by 5 years
after diagnosis. Disease progression is worse in children
compared with adults.5
The impact of medical management on disease pro-
gression and on surgical rates remains controversial.6–26
We previously reported, using data from this same
patient registry, that the 5-year risk of bowel surgery in
pediatric CD was 13.8%.27 Retrospective pediatric
studies have reported the 5-year risk of surgery to be
between 14.2% and 34%.28–30
Our primary goal was to determine the 10-year surgical
risk in children with CD. Our secondary goal was to deter-
mine if the early use of biologics (anti–tumor necrosis
factor [TNF]a) influenced the risk of disease progression.Materials and Methods
Study Population
The Pediatric Inflammatory Bowel Disease Collabora-
tive Research Group registry was established by 26 North
American pediatric inflammatory bowel disease (IBD)
centers in 2002 to study the contemporary natural history
of IBD. Newly diagnosed children 16 years of age and
younger were enrolled. Patients were managed according
to the practice of their individual physician. Uniform data
were collected at diagnosis, 30 days after diagnosis, and
then quarterly and during hospitalizations. Between
January 2002 and December 2014, the registry enrolled
2116 pediatric IBD patients. The 1442 CD patients (68%
of the total) constitute the study population of this report.Outcomes
The outcomes of interest were time from diagnosis to
(a) first intestinal surgery and (b) time to progression to
stricturing and/or penetrating disease.Description of Variables
Day 0 was defined as the date of initial diagnosis. The
study end date for patients who had a CD-related surgery
was the date of the first bowel surgery. The patients who
did not have surgery had a study end date defined by the
last quarter of follow-up evaluation, which also was used
to censor values in time-to-event analyses. Bowel sur-
gery was defined as intestinal resection with primary
anastomosis or diverting ostomy (including subtotal and
total colectomy) or strictureplasty. Other surgical pro-
cedures such as abdominal or perianal abscess drainage,
or fistulotomy, were excluded. Family history of IBD was
defined as having an affected mother, father, or sibling.
Disease location was recorded within 30 days of diag-
nosis. The presence of endoscopic, histologic, or radio-
logic disease was recorded for the esophagus,
gastroduodenum, jejunum, ileum, right colon, transverse
colon, left colon, and for disease of the sigmoid colon
and/or rectum. Disease location was classified as
esophagus to jejunum, ileum to right colon, and trans-
verse colon to rectum. Disease behavior was recorded at
baseline, 30 days after diagnosis, and then quarterly.
Disease behavior was defined as nonstricturing, non-
penetrating (inflammatory) disease (B1), stricturing
(B2), and penetrating disease (B3). If a patient had a
missing disease behavior for a particular quarter, the
previous quarter’s disease behavior was carried
forward. Disease progression was defined as change
from inflammatory only to either stricturing or pene-
trating or both. Regarding treatments, use of biologics
was considered “early” if patients were started during
the first quarter after diagnosis and completed their
induction phase.20 Immunomodulator use was defined if
the use of 6-mercaptopurine, azathioprine, or metho-
trexate was documented for more than 1 quarter.
Statistical Methods
The Kaplan–Meier method was used to estimate
survival functions with 95% CIs for first bowel surgery,
first nonbowel surgery, and all first CD-related surgery.
The Wilcoxon weighting of the chi-square statistic was
used when comparing subsets of patients (weighting by
changing sample size over time). The family wise a value
was maintained at .05 across multiple comparisons using
a Tukey adjustment of the raw P values. Proportional
hazards (Cox) regression with time-varying covariates
was used to model time-to-event outcomes with time-
varying covariates. Disease severity was dummy coded
Patient characteristics (N ¼ 1442)
Age
<6 y 56 3.90%
>6 y 1386 96.10%
Male sex 850 59%
Race
Caucasian 1240 86.00%




Duration of follow-up period, y Median, 4.7 Range, 1–12
Disease behavior at diagnosis
B1, inflammatory 1291 89.50%
B2, stricturing 51 3.50%
B3, penetrating 27 1.90%
B2 and B3, stricturing and
penetrating
11 0.70%
Timing of patients enrolled
Enrolled before 2008 913 63.60%
Enrolled after 2008 529 36.70%
Table 1. Characteristics of the 1442 Patients With CD 
Diagnosed Between 2002 and 2014as stricturing or penetrating disease relative to inflam-
matory disease. Age was treated as continuous. All
statistical analyses were performed using SAS version
9.4 (The SAS Institute, Inc, Cary, NC).
The protocol for the Pediatric Inflammatory
Bowel Disease Collaborative Research Group registry
was approved by the institutional review boards of
all participating institutions, and informed consent/




Demographics and disease characteristics for the
1442 CD patients enrolled in our study are shown
in Table 1.
Risk of Crohn’s Disease–Related Bowel Surgery
The Kaplan–Meier estimated risk of CD-related bowel
surgery was 4% at 1 year, 13% at 5 years, and 26% at
10 years (Figure 1A). A total of 241 subjects underwent
any type of surgery, 171 of these had bowel-related
surgery (Table 2).
Figure 1B shows the monthly occurrence of the 171
bowel surgeries since the diagnosis. Two patients (1%)
underwent bowel resection at diagnosis and were
not included in our analyses, 66% of first bowel sur-
geries occurred within 36 months from diagnosis and
the remaining 33% occurred over the last 84 months of
the study.Specific Risks for Surgery
Patients with stricturing and/or penetrating disease
behavior at diagnosis were at a significantly higher risk
of surgery over time (P ¼ .001) (Figure 1C). Table 3
shows the risk of surgery for subsets of patients based
on age, sex, and disease behavior. Overall, our analyses
show that over time neither age of the patient (P ¼ .05),
disease location at diagnosis (P ¼ .8), year of diagnosis
(P ¼ .6), nor presence of perianal disease (P ¼ .4) predict
differences in the risk of surgery. There was also no
difference in the 5-year risk of surgery between patients
who entered the study between 2002 and 2007 and
those enrolled between 2008 and 2014 (Figure 2A),
despite an increased use of biologics (Figure 2B) and the
earlier initiation of biologics (Figure 2C).
No significant effects on disease progression were
identified for nonbiologic treatments.
Impact of Treatment on Disease Progression
Among patients who received a biologic agent at any
time during the study (including the first 3 months), the
risk of disease progression to stricturing or penetrating
disease was statistically significantly reduced by biologic
use as analyzed by proportional hazards (Cox) regres-
sion with biologic use as a time-varying covariate
(hazard ratio, 0.85; 95% CI, 0.76–0.95; P ¼ .005). No
significant effect on surgery was found.
We examined the impact of biologics on disease
progression in children with inflammatory (B1) disease.
Of the 1291 patients with B1 disease at diagnosis,
145 patients had been started by their pediatric gastro-
enterologists on biologics within the first 3 months after
diagnosis. Analyses (Figure 3A) of those who were
treated early showed that disease progression from B1 to
B2 or B3 after 5 years was decreased when compared
with those not receiving early biologics (P < .005). No
statistically significant effect was found on progression
to surgery. We could not show a significant impact on
any outcome in those groups in which the biologics were
started after the first 3 months.
Interestingly, Figure 3B shows that patients with B1
disease, exposed to biologics in the first quarter of their
disease, seemed more likely to have early surgery than
those with B1 disease who were not started on biologics.
Discussion
The long-term effect of current IBD therapies, espe-
cially biologics, in children is not clear.25,26 Recently
Kugathasan et al20 showed that children enrolled in the
Risk Stratification and Identification of Immunogenic and
Microbial Markers of Rapid Disease Progression in Chil-
dren with Crohn’s (RISK)20 cohort, who received early
(within the first 3 months from diagnosis) anti-TNFa
therapy, showed a reduction in penetrating disease but
Figure 1. (A) Cumulative incidence of CD bowel-related surgery over 10 years. The x-axis represents the years since the
diagnosis. The y-axis represents surgery-free survival. (B) Occurrences of bowel surgery since the diagnosis. The x-axis
represents each month (and longer time periods) since the diagnosis. The y-axis represents the average number of surgeries
performed per month in each time period (as recorded in the legend box). (C) Cumulative incidence of bowel surgery stratified
by disease behavior at diagnosis. B1, inflammatory; B2, stricturing; B3, penetrating; B2 and B3, both stricturing and
penetrating.
Table 3. Risk of Surgery by Demographics of CD
Kaplan–Meier estimatednot stricturing disease within their first 4 years after
diagnosis. Our study was not able to show an effect on
disease progression within a timeframe similar to that of
the RISK study. We were, however, able to show an
overall effect on disease progression after 5 years. The
difference reflects the differences in study populations.
The RISK study20 included only children who were still
classified as having inflammatory (B1) disease at 90
days after diagnosis, excluding children with disease
progression within 3 months of diagnosis. We includedTable 2. First Bowel Surgery: 171 Patients
Ileocecal resection 74
Segmental resection and anastomosis of small bowel 62
Segmental resection and anastomosis of large bowel 15
Ostomy of small bowel 18
Ostomy of large bowel 11
Strictureplasty 3
Colectomy with ostomy 1
Colectomy with IPAA 1
NOTE. Table does not include patients who had surgery related to intravenous
access devices appendectomy, anal examination under anesthesia, washout
of fistula, local abscess drainage, G-tube insertion, and so forth. Table may
include more than 1 procedure at first surgery (ie, resection þ ostomy).
IPAA, ileal pouch–anal anastomosis.those children. By including many children in whom
early disease progression already had taken place, we
lessened our ability to show an early effect on their
group as a whole. More than 15% of our cohort already
had their first bowel-related surgery in the first 90 days
after diagnosis (Figure 1B).surgery rate Time since diagnosis, y
Risk of bowel surgery 1 5 10 Significance
Age at diagnosis NS
<6 y 3.80% 13% 21.60%
>6 y 4% 13% 26.90%
Sex NS
Males 3% 12.50% 20%




B1 2.50% 11.50% 24.50%
B2 2.50% 37% —
B3 30% 46% 46%
B2 and B3 50% 51% –
Figure 2. (A) Cumulative incidence of bowel surgery stratified by year of diagnosis (diagnosed before 2008 to after 2008). The
x-axis shows the years since the diagnosis, and the y-axis shows surgery-free survival. The 5-year surgery-free survival curves
of both groups overlap, indicating no change in risk of surgery from 2002 to 2014. (B) Percentage of patients on biologics at
any given time stratified by year of diagnosis (diagnosed before 2008 or after 2008). The x-axis shows the years since the
diagnosis, and the y-axis shows the percentage of patients on biologics. This confirms the increasing use of biologics. (C)
Time to initiation of biologics stratified by year of diagnosis (diagnosed before 2008 vs after 2008). The x-axis shows the years
since the diagnosis, and the y-axis shows biologics-free survival. This confirms the increasing early use of biologics.The 5-year risk of surgery in our prospective cohort
was 13%, and the 10-year risk was 26% (Figure 1A).
This is identical to a recent single-center retrospective
study in children published by an Israeli group.28
However, the risk is lower than all other published
pediatric and adult studies.29,30 The difference may be
related to this being a true inception cohort of patients,
or to the era of diagnosis. The surgical rates are less
when compared with most of the population-based
cohorts in adults, suggesting that the risk of surgery
may be different in pediatric Crohn’s disease compared
with adult-onset Crohn’s disease. However, the 5-year
risk of surgery did not change significantly when
comparing cohorts diagnosed between 2002 and 2007
(13.8%)27 and 2008 and 2014 (13%) (Figure 2A). This is
true despite the documented earlier and increasingly
frequent use of biologics over the course of the study
(Figure 2B and C).
Disease behavior (inflammatory vs stricturing vs
penetrating) at diagnosis was the best predictor of sur-
gery (Figure 1C). None of the other disease characteris-
tics at diagnosis such as disease location, sex, age at
onset, year of diagnosis, or center from which patient
was recruited predicted surgery.Although several studies have shown that disease
location does not predict the risk of surgery,31–33 a
recent study by Cleynen et al,14 one of the larger
genotype-phenotype correlation studies of IBD, showed
that the risk of surgery was low in colonic disease
compared with those with ileocolonic/ileal disease.
Our results reflect the natural progression of CD
over 10 years. Our analysis shows that the use of
biologics is associated with slowing disease progression
from inflammatory to stricturing/penetrating (hazard
ratio, 0.85; 95% CI, 0.76–0.95; P ¼ .005). Our work
extends the findings recently reported by Kugathasan
et al,20 that early anti-TNFa therapy was associated
with a reduction in penetrating disease generally
occurring within a 2-year period. They suggest that a
specific ileal extracellular matrix protein gene signature
present at diagnosis predicted stricturing disease in
pediatric Crohn’s disease. We suggest that their exclu-
sion of patients with disease progression occurring in
the first 90 days skews their study population toward a
less severe group than we are reporting and toward a
group more able to show response to early treatment.
Most importantly, both reports support the positive
impact of early therapy with biologics to prevent the
Figure 3. (A) Disease progression from inflammatory to stricturing and/or penetrating compared between the early initiation of
biologics group (use of biologics in the first 3 months) and the no early exposure to biologics groups (did not receive biologics
in the first 3 months). The x-axis show the follow-up period in years since the diagnosis, and the y-axis shows the proportion of
patients without disease progression (ie, change of behavior from inflammatory to stricturing and/or penetrating.) (B)
Cumulative risk of surgery among early initiation of biologics (within the first 3 months) compared with those who did not receive
biologics in the first 3 months. The x-axis shows the years since the diagnosis, and the y-axis shows surgery-free survival. Note
that those patients who received biologics within the first 3 months after diagnosis showed shorter surgery-free survival.significant complications associated with disease
progression.
It should be noted that we found that in the group
receiving early biologics (n ¼ 145), the risk of surgery
appears to be increased paradoxically in the first 5 years
after diagnosis (Figure 2B). This suggests that our
practicing pediatric gastroenterologists may have
selected the sicker patients to start biologics. If this is the
case then this introduces a bias that strengthens our
findings because it would be the sicker patients who are,
in our study, experiencing the better long-term outcome
(ie, less disease progression).
The strengths of our study include its long-term
follow-up period, its large sample size, and being a true
inception cohort (ie, inclusion of children within the first
30 days from diagnoses). These enable us to better
assess temporal trends associated with the incidence of
surgery. There were limitations, however, of the study.
This study was started more than 15 years ago and
conceived before our current ability to collect and pro-
cess biological samples and to monitor anti-TNFa blood
levels. As a registry-based study, disease location data
were not universally available on follow-up evaluation,
endoscopic and pathologic data were not collected
uniformly, and variation in practice at different centers
may have influenced the results. Even though details of
the treatment were documented, we do not have infor-
mation about whether therapeutic drug monitoring of
biologics or immunomodulators were used to optimize
these treatments during the study. Another important
limitation was the decrease in the number of patients
over time, similar to other prospective cohort studies.
Some of these limitations also limit the analytic
approaches available to us.
Overall, this study provides important information
about temporal trends of surgical risk in pediatricCrohn’s disease. The initial 5-year risk of surgery has not
changed over the 12 years of our study despite the use of
newer therapies. We believe that this may reflect sig-
nificant subclinical and clinical disease progression
before diagnosis and before current medications capable
of altering disease course are used. However owing to
limitation of the registry model, we could not prove that
surgery would decrease with earlier or more aggressive
biologic use.
Taken together, our work and the work of Kugatha-
san et al20 present a picture consistent with the view that
a critical factor in preventing bowel complications of IBD
is starting effective treatment early, before the accumu-
lation of significant bowel damage.References
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